{"id":25174,"date":"2022-10-12T15:37:00","date_gmt":"2022-10-12T07:37:00","guid":{"rendered":"https:\/\/flcube.com\/?p=25174"},"modified":"2025-02-03T15:42:28","modified_gmt":"2025-02-03T07:42:28","slug":"beigene-partners-with-amoy-diagnostics-for-companion-diagnostics-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=25174","title":{"rendered":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development"},"content":{"rendered":"\n

China-based biotech BeiGene Inc. (HKG: 6160<\/a>, SHA: 688235<\/a>, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx\u2019s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene\u2019s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene\u2019s targeted therapies.<\/p>\n\n\n\n

AmoyDx: Company Profile and Technology<\/strong>
Founded in 2008, AmoyDx is a leading diagnostic company known for its innovative technologies, including ADx ARMS, Super ARMS, ddCapture, and ADx HANDLE. These technologies have attracted partnerships with major pharmaceutical companies such as AstraZeneca, Johnson & Johnson, Amgen, Eli Lilly, Merck, Eisai, and Hengrui Medicine. AmoyDx\u2019s HER2 detection kits are designed to provide accurate and reliable diagnostic results, supporting the use of targeted therapies in cancer treatment.<\/p>\n\n\n\n

Future Outlook<\/strong>
The partnership between BeiGene and AmoyDx underscores the growing importance of companion diagnostics in the development of targeted cancer therapies. By leveraging AmoyDx\u2019s advanced detection technologies, BeiGene aims to streamline the regulatory approval process for its drugs and enhance the precision of its therapeutic offerings. This collaboration is expected to contribute to improved patient outcomes and the advancement of personalized medicine.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[330,241,1130,130,185,2092,30,16,350,199,2586,847,149,120,846,848],"class_list":["post-25174","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-amgen","tag-amoy-diagnostics","tag-amoydx","tag-astrazeneca","tag-beigene","tag-beone-medicines","tag-biotech","tag-cancer","tag-eisai","tag-eli-lilly","tag-hengrui-pharmaceuticals","tag-hkg-6160","tag-johnson-johnson","tag-merck","tag-nasdaq-bgne","tag-sha-688235"],"yoast_head":"\nBeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx\u2019s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene\u2019s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene\u2019s targeted therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=25174\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=25174\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-12T07:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-03T07:42:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development\",\"datePublished\":\"2022-10-12T07:37:00+00:00\",\"dateModified\":\"2025-02-03T07:42:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174\"},\"wordCount\":217,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Amgen\",\"Amoy Diagnostics\",\"AmoyDx\",\"AstraZeneca\",\"BeiGene\",\"BeOne Medicines\",\"Biotech\",\"Cancer\",\"Eisai\",\"Eli Lilly\",\"Hengrui Pharmaceuticals\",\"HKG: 6160\",\"Johnson & Johnson\",\"Merck\",\"NASDAQ: BGNE\",\"SHA: 688235\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25174#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=25174\",\"name\":\"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-10-12T07:37:00+00:00\",\"dateModified\":\"2025-02-03T07:42:28+00:00\",\"description\":\"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx\u2019s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene\u2019s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene\u2019s targeted therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=25174\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=25174#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development - Insight, China's Pharmaceutical Industry","description":"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx\u2019s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene\u2019s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene\u2019s targeted therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=25174","og_locale":"en_US","og_type":"article","og_title":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=25174","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-10-12T07:37:00+00:00","article_modified_time":"2025-02-03T07:42:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=25174#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=25174"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development","datePublished":"2022-10-12T07:37:00+00:00","dateModified":"2025-02-03T07:42:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=25174"},"wordCount":217,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Amgen","Amoy Diagnostics","AmoyDx","AstraZeneca","BeiGene","BeOne Medicines","Biotech","Cancer","Eisai","Eli Lilly","Hengrui Pharmaceuticals","HKG: 6160","Johnson & Johnson","Merck","NASDAQ: BGNE","SHA: 688235"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=25174#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=25174","url":"https:\/\/flcube.com\/?p=25174","name":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-10-12T07:37:00+00:00","dateModified":"2025-02-03T07:42:28+00:00","description":"China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has entered into a partnership with compatriot firm Amoy Diagnostics Co., Ltd (AmoyDx). The collaboration allows AmoyDx\u2019s HER2 gene IHC (immunohistochemistry) and FISH (fluorescence in situ hybridization) detection kits to support BeiGene\u2019s filings for its drugs as companion diagnostics (CDx). This strategic alliance aims to enhance the development and regulatory approval process for BeiGene\u2019s targeted therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=25174#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=25174"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=25174#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"BeiGene Partners with Amoy Diagnostics for Companion Diagnostics Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25174","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=25174"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25174\/revisions"}],"predecessor-version":[{"id":25175,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/25174\/revisions\/25175"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=25174"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=25174"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=25174"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}